Marketed Biologics In 2023 By Type
Source: ISR Reports
In Q2, 2018 ISR surveyed 100 outsourcers of bioprocessing / biologic API manufacturing to learn what they predict their company’s biologics portfolio will look like five years from now. On average, respondents anticipate monoclonal antibodies will account for one-third of their company’s biologics portfolio. Cell therapies followed at a distance for second position, averaging at 13 percent of the aggregated biologics portfolio.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more